The GCC was better able to go and educate the important referring providers, educate the types of OMNI surgeons that were more likely to be ready to go sooner. And so it’s through that very tight collaboration between GCC and surgical sales rep that more efficient higher yield better quality standalone market development was happening. So what we’ve done is we’ve taken that entire 20 member GCC team and recently integrated them entirely within the surgical sales infrastructure. And we’re super excited now to replicate what we saw was already happening in a handful of territories, where we were seeing better productivity on standalone market development and better uplift there. We think that we’re institutionalizing it now with the GCC is under the leadership of the regional directors on our salesforce.
And we expect now, those other territories to follow soon.
Craig Bijou: Got it. One follow-up. I mean any timing €“ or I mean expected timing on how quickly you think that you can see some uptick in other territories?
Paul Badawi: I think.
Jesse Selnick: We €“ yeah, go ahead, Paul.
Paul Badawi: I think we’re seeing standalone uptick now, I mean, if you just some barometers. It’s hard to track with any accuracy, again, it’s OMNI, right? It’s the same device. We don’t have a combo cataract device and a standalone device. OMNI has a very broad indication for combo cataract and standalone and at a severity of disease. So it’s tricky. It’s tricky to track in that way, because it’s the same device. But based on, first of all, our performance and our growth, I think, it gets all rolled up into that. So we can expect that to continue. And then, just the discussions we’re having €“ we have a large commercial infrastructure and the discussions we’re having with our surgeon customers and the awareness of standalone that we’re driving and the feedback from our customers on standalone and the way that we’re training doctors today from the get-go , when they do their first 10 cases, we’re institutionalizing some best practices, we’ll do 7 combo cataract cases and 3 standalone cases if possible.
So those are the kinds of things that are happening with increasing frequency. It’s tangible to us. The chatter amongst the surgeon community around standalone continues to grow. And, I think, all of those things are very good barometers of standalone market development, standalone progress, in an area that’s otherwise tricky to assess with any €“ like right now any real accuracy again, because the product OMNI is the same successful product and combo cataract isn’t standalone.
Craig Bijou: Got it. Thanks for the color, guys.
Paul Badawi: Sure.
Operator: Thank you. And I see no further questions in the queue. I’d now like to turn the conference back to Paul Badawi for closing remarks.
Paul Badawi: Well, thank you, Chris, and thank you all. I appreciate everyone’s continued interest in Sight Sciences. I appreciate your time. I hope everyone is well. And have a great rest of your day.
Operator: Thank you. This concludes today’s conference call. Thank you all for participating. You may now disconnect. And have a pleasant day.
